• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 主蛋白酶复制酶多蛋白切割和底物特异性的结构基础。

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2.

机构信息

Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.

School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.

出版信息

Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2117142119. doi: 10.1073/pnas.2117142119. Epub 2022 Apr 5.

DOI:10.1073/pnas.2117142119
PMID:35380892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9172370/
Abstract

The main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key enzyme, which extensively digests CoV replicase polyproteins essential for viral replication and transcription, making it an attractive target for antiviral drug development. However, the molecular mechanism of how Mpro of SARS-CoV-2 digests replicase polyproteins, releasing the nonstructural proteins (nsps), and its substrate specificity remain largely unknown. Here, we determine the high-resolution structures of SARS-CoV-2 Mpro in its resting state, precleavage state, and postcleavage state, constituting a full cycle of substrate cleavage. The structures show the delicate conformational changes that occur during polyprotein processing. Further, we solve the structures of the SARS-CoV-2 Mpro mutant (H41A) in complex with six native cleavage substrates from replicase polyproteins, and demonstrate that SARS-CoV-2 Mpro can recognize sequences as long as 10 residues but only have special selectivity for four subsites. These structural data provide a basis to develop potent new inhibitors against SARS-CoV-2.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的主要蛋白酶(Mpro)是一种关键酶,它广泛消化 CoV 复制酶多蛋白,这些多蛋白对病毒复制和转录至关重要,因此它成为抗病毒药物开发的有吸引力的靶点。然而,SARS-CoV-2 的 Mpro 如何消化复制酶多蛋白并释放非结构蛋白(nsps)的分子机制以及其底物特异性在很大程度上仍不清楚。在这里,我们确定了 SARS-CoV-2 Mpro 在静止状态、预切割状态和切割后状态的高分辨率结构,构成了完整的底物切割循环。这些结构显示了多蛋白加工过程中发生的精细构象变化。此外,我们还解决了 SARS-CoV-2 Mpro 突变体(H41A)与来自复制酶多蛋白的六个天然切割底物复合物的结构,并证明 SARS-CoV-2 Mpro 可以识别长达 10 个残基的序列,但仅对四个亚位点具有特殊选择性。这些结构数据为开发针对 SARS-CoV-2 的有效新型抑制剂提供了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/f07e24628a87/pnas.2117142119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/f830e7c6eabe/pnas.2117142119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/ad165959655f/pnas.2117142119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/08a331d861d6/pnas.2117142119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/e284662c31df/pnas.2117142119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/f07e24628a87/pnas.2117142119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/f830e7c6eabe/pnas.2117142119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/ad165959655f/pnas.2117142119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/08a331d861d6/pnas.2117142119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/e284662c31df/pnas.2117142119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ba0/9172370/f07e24628a87/pnas.2117142119fig05.jpg

相似文献

1
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2.SARS-CoV-2 主蛋白酶复制酶多蛋白切割和底物特异性的结构基础。
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2117142119. doi: 10.1073/pnas.2117142119. Epub 2022 Apr 5.
2
Kinetic comparison of all eleven viral polyprotein cleavage site processing events by SARS-CoV-2 main protease using a linked protein FRET platform.利用连接蛋白荧光共振能转移平台对 SARS-CoV-2 主蛋白酶的所有 11 种病毒多蛋白切割位点加工事件进行动力学比较。
J Biol Chem. 2024 Jun;300(6):107367. doi: 10.1016/j.jbc.2024.107367. Epub 2024 May 15.
3
The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.主要蛋白酶和RNA依赖性RNA聚合酶是新型冠状病毒的两个主要靶点。
Biochem Biophys Res Commun. 2021 Jan 29;538:63-71. doi: 10.1016/j.bbrc.2020.10.091. Epub 2020 Nov 21.
4
SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense.SARS-CoV-2 主要蛋白酶切割 MAGED2 以拮抗宿主抗病毒防御。
mBio. 2023 Aug 31;14(4):e0137323. doi: 10.1128/mbio.01373-23. Epub 2023 Jul 13.
5
Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL main protease (Mpro) from proteomic identification of P6-P6' active site specificity.通过蛋白质组学鉴定 P6-P6' 活性位点特异性优化 SARS-CoV-2 3CL 主要蛋白酶(Mpro)的淬灭荧光肽底物
J Virol. 2024 Jun 13;98(6):e0004924. doi: 10.1128/jvi.00049-24. Epub 2024 May 14.
6
Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2.蛋白质结构异质性:SARS-CoV 和 SARS-CoV-2 主要蛋白酶进行蛋白水解识别的基础假说。
Biochimie. 2021 Mar;182:177-184. doi: 10.1016/j.biochi.2021.01.010. Epub 2021 Jan 20.
7
SARS-CoV-2 polyprotein substrate regulates the stepwise M cleavage reaction.SARS-CoV-2 多蛋白底物调节逐步 M 裂解反应。
J Biol Chem. 2023 May;299(5):104697. doi: 10.1016/j.jbc.2023.104697. Epub 2023 Apr 10.
8
X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation.SARS-CoV-2 主要蛋白酶多蛋白切割位点的 X 射线晶体学表征,这些切割位点对于病毒的加工和成熟至关重要。
Nat Commun. 2022 Sep 3;13(1):5196. doi: 10.1038/s41467-022-32854-4.
9
Biochemical and structural insights into SARS-CoV-2 polyprotein processing by Mpro.SARS-CoV-2 多蛋白由 Mpro 加工的生化和结构见解。
Sci Adv. 2022 Dec 9;8(49):eadd2191. doi: 10.1126/sciadv.add2191.
10
Unmasking the Conformational Stability and Inhibitor Binding to SARS-CoV-2 Main Protease Active Site Mutants and Miniprecursor.揭开 SARS-CoV-2 主蛋白酶活性位点突变体和前体抑制剂结合的构象稳定性。
J Mol Biol. 2022 Dec 30;434(24):167876. doi: 10.1016/j.jmb.2022.167876. Epub 2022 Nov 2.

引用本文的文献

1
The kinetics of nsp7-11 polyprotein processing and impact on complexation with nsp16 among human coronaviruses.人类冠状病毒中nsp7 - 11多蛋白加工的动力学及其对与nsp16复合的影响。
Nat Commun. 2025 Sep 9;16(1):8244. doi: 10.1038/s41467-025-61554-y.
2
A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross-Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 Variants.一种多抗原广谱冠状病毒疫苗可诱导针对多种新冠病毒变异株引起的感染和疾病产生强效且持久的交叉保护。
Res Sq. 2025 Aug 20:rs.3.rs-7208748. doi: 10.21203/rs.3.rs-7208748/v1.
3
The main protease (M) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII.

本文引用的文献

1
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
2
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.严重急性呼吸综合征冠状病毒2型主要蛋白酶与蛋白酶抑制剂PF-07321332复合物的晶体结构
Protein Cell. 2022 Sep;13(9):689-693. doi: 10.1007/s13238-021-00883-2. Epub 2021 Oct 22.
3
Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease.
新型冠状病毒(SARS-CoV-2)的主要蛋白酶(M)通过激活凝血因子VII和FXII在体外引发血浆凝固。
Commun Biol. 2025 Aug 1;8(1):1145. doi: 10.1038/s42003-025-08570-2.
4
Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning.机器学习揭示的SARS-CoV-2 Mpro抑制剂中结合亲和力与类药性之间的拮抗趋势
Viruses. 2025 Jun 30;17(7):935. doi: 10.3390/v17070935.
5
Design and Evaluation of Andrographolide Analogues as SARS-CoV-2 Main Protease Inhibitors: Molecular Modeling and in vitro Studies.穿心莲内酯类似物作为新型冠状病毒主要蛋白酶抑制剂的设计与评价:分子模拟与体外研究
Drug Des Devel Ther. 2025 May 15;19:3907-3924. doi: 10.2147/DDDT.S514193. eCollection 2025.
6
Distal protein-protein interactions contribute to nirmatrelvir resistance.远端蛋白质-蛋白质相互作用导致对奈玛特韦耐药。
Nat Commun. 2025 Feb 1;16(1):1266. doi: 10.1038/s41467-025-56651-x.
7
Recognition and cleavage of human tRNA methyltransferase TRMT1 by the SARS-CoV-2 main protease.新型冠状病毒2型主要蛋白酶对人tRNA甲基转移酶TRMT1的识别与切割
Elife. 2025 Jan 7;12:RP91168. doi: 10.7554/eLife.91168.
8
Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents.含谷氨酰胺等排体的新型冠状病毒3CL蛋白酶和人组织蛋白酶L双重抑制剂是抗新型冠状病毒药物。
J Am Chem Soc. 2025 Jan 15;147(2):1631-1648. doi: 10.1021/jacs.4c11620. Epub 2025 Jan 2.
9
An isothermal calorimetry assay for determining steady state kinetic and Ensitrelvir inhibition parameters for SARS-CoV-2 3CL-protease.一种用于测定新型冠状病毒 3CL 蛋白酶稳态动力学和恩昔替尼抑制参数的等温滴定量热法检测。
Sci Rep. 2024 Dec 31;14(1):32175. doi: 10.1038/s41598-024-81990-y.
10
Catalytic Mechanism of SARS-CoV-2 3-Chymotrypsin-Like Protease as Determined by Steady-State and Pre-Steady-State Kinetics.通过稳态和预稳态动力学确定的新型冠状病毒3-胰凝乳蛋白酶样蛋白酶的催化机制
ACS Catal. 2024 Nov 27;14(24):18292-18309. doi: 10.1021/acscatal.4c04695. eCollection 2024 Dec 20.
基于结构的 SARS-CoV-2 主蛋白酶靶向的吡仑帕奈衍生药效团的设计。
Structure. 2021 Aug 5;29(8):823-833.e5. doi: 10.1016/j.str.2021.06.002. Epub 2021 Jun 22.
4
Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.埃布斯硒啉及其衍生物对 SARS-CoV-2 主蛋白酶的抑制机制。
Nat Commun. 2021 May 24;12(1):3061. doi: 10.1038/s41467-021-23313-7.
5
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.高通量筛选鉴定出已上市药物为 SARS-CoV-2 PLpro 抑制剂。
Protein Cell. 2021 Nov;12(11):877-888. doi: 10.1007/s13238-021-00836-9. Epub 2021 Apr 17.
6
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.X射线筛选鉴定出新型冠状病毒主要蛋白酶的活性位点和变构抑制剂。
Science. 2021 May 7;372(6542):642-646. doi: 10.1126/science.abf7945. Epub 2021 Apr 2.
7
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.用于开发 SARS-CoV-2 3CL 蛋白酶抑制剂的先导化合物。
Nat Commun. 2021 Apr 1;12(1):2016. doi: 10.1038/s41467-021-22362-2.
8
Antivirals with common targets against highly pathogenic viruses.针对高致病性病毒具有共同靶点的抗病毒药物。
Cell. 2021 Mar 18;184(6):1604-1620. doi: 10.1016/j.cell.2021.02.013.
9
SARS-CoV-2 M inhibitors with antiviral activity in a transgenic mouse model.具有抗病毒活性的 SARS-CoV-2 M 抑制剂在转基因小鼠模型中。
Science. 2021 Mar 26;371(6536):1374-1378. doi: 10.1126/science.abf1611. Epub 2021 Feb 18.
10
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.一种含有吲哚结构的小分子化合物抑制 SARS-CoV-2 的主要蛋白酶并阻断病毒复制。
Nat Commun. 2021 Jan 28;12(1):668. doi: 10.1038/s41467-021-20900-6.